Skip to content
Inciteful Med

The Long Game: Maintenance and Relapse

Last updated:

Maintenance therapy, typically with Lenalidomide, helps keep Multiple Myeloma in remission after transplant. Relapse is common but often starts as a rise in lab numbers (biochemical) before symptoms appear. New therapies like CAR-T and bispecific antibodies offer options when standard drugs stop working.

Key Takeaways

  • • Maintenance therapy helps keep myeloma in remission, often using daily Lenalidomide indefinitely.
  • • The REMS program requires monthly patient surveys to access Lenalidomide due to safety risks.
  • • Biochemical relapse means lab numbers rise before physical symptoms appear, often prompting a treatment switch.
  • • High-risk patients may require a doublet maintenance therapy combining two different drugs.
  • • Newer immunotherapies like CAR-T and bispecifics target BCMA when standard treatments stop working.

After transplant, most patients take Maintenance Therapy to keep the cancer asleep [1].

  • Standard: Lenalidomide (Revlimid) pill daily. Usually continued until it stops working [2].
  • REMS Program: Because Revlimid can cause birth defects, it is controlled by a strict program called REMS. You will need to complete a quick survey every month to get your prescription.
  • High-Risk: Patients often take a “doublet” (Revlimid + Velcade or Ninlaro) [3].

Understanding Relapse

Myeloma usually comes back. This is expected. Do not panic.

  • Biochemical Relapse: Your lab numbers (M-spike/Light Chains) rise. No symptoms yet.
  • Clinical Relapse: Symptoms (pain, kidney issues) return.
  • Action: Doctors often switch treatments when numbers rise significantly, before symptoms appear [4].

The Future: CAR-T and Bispecifics

When standard drugs stop working, we now have powerful immunotherapies that target BCMA on myeloma cells [5].

  • CAR-T (Cilta-cel, Ide-cel): Your own T-cells are engineered to kill cancer. One-time infusion. Extremely high response rates [6]. Now approved for earlier lines (after 1-2 prior therapies) [7].
  • Bispecifics (Teclistamab): “Off-the-shelf” antibodies that connect T-cells to cancer. Weekly/bi-weekly shots [8].

There are many “lines” of therapy. Myeloma is a marathon, not a sprint.

Frequently Asked Questions

What is maintenance therapy for Multiple Myeloma?
Maintenance therapy involves taking medication, commonly Lenalidomide (Revlimid), to keep the cancer in remission after a transplant. It is usually continued daily until the drug stops working or side effects become unmanageable.
What is the REMS program for Revlimid?
The REMS program is a mandatory safety system for patients taking Lenalidomide because the drug can cause severe birth defects. You must complete a quick monthly survey to confirm safety measures before receiving your prescription.
What is the difference between biochemical and clinical relapse?
A biochemical relapse occurs when lab numbers like M-spike or Light Chains rise, but you feel fine. A clinical relapse involves the return of physical symptoms such as pain or kidney issues.
Do high-risk patients need different maintenance therapy?
High-risk patients often take a combination of two drugs, known as a "doublet," for maintenance. This typically involves adding a drug like Velcade or Ninlaro to the standard Lenalidomide regimen.
What are CAR-T and bispecific therapies?
CAR-T therapy and bispecific antibodies are advanced immunotherapies used when standard drugs stop working. They target the BCMA protein on cancer cells to help your immune system attack the myeloma.

Questions for Your Doctor

  • • How long will I be on Lenalidomide maintenance?
  • • What is the 'REMS' program and what surveys do I need to complete?
  • • If I am high-risk, should I be on two maintenance drugs?
  • • What defines a 'biochemical relapse' for me?
  • • Am I eligible for CAR-T therapy if I relapse?

Questions for You

  • • How do I feel about long-term daily medication?
  • • Am I ready to track my numbers so I catch a relapse early (biochemical) rather than late (symptoms)?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.

    Syed YY

    Drugs 2017; (77(13)):1473-1480 doi:10.1007/s40265-017-0795-0.

    PMID: 28791622
  2. 2

    Maintenance therapy for multiple myeloma in the era of novel agents.

    Facon T

    Hematology. American Society of Hematology. Education Program 2015; (2015()):279-85 doi:10.1182/asheducation-2015.1.279.

    PMID: 26637734
  3. 3

    Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma.

    Marneni N, Chakraborty R

    Current hematologic malignancy reports 2021; (16(2)):148-161 doi:10.1007/s11899-021-00631-7.

    PMID: 33876390
  4. 4

    Eliminating the need for sequential confirmation of response in multiple myeloma.

    Claveau JS, Kapoor P, Binder M, et al.

    Blood 2025; (146(7)):802-805 doi:10.1182/blood.2024027949.

    PMID: 40489635
  5. 5

    Clinical updates of B‑cell maturation antigen‑targeted therapy in multiple myeloma (MM) and relapsed/refractory MM (Review).

    Xing R, Wang M, Wang L, et al.

    International journal of molecular medicine 2025; (55(2)).

    PMID: 39670288
  6. 6

    From Trials to Practice: A 2025 Review of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Efficacy Across Clinical Studies and Real-World Evidence.

    Pleitez HG, Saowapa S, Maldonado AO, et al.

    European journal of haematology 2025; (115(6)):533-546 doi:10.1111/ejh.70025.

    PMID: 40928436
  7. 7

    Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy.

    Goel U, Zanwar S, Cowan AJ, et al.

    Cancer management and research 2025; (17()):357-372 doi:10.2147/CMAR.S510408.

    PMID: 39990276
  8. 8

    Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment.

    Navab R, Futela P, Kumari V, et al.

    Iranian journal of medical sciences 2025; (50(1)):1-10 doi:10.30476/ijms.2024.101739.3446.

    PMID: 39957814

This guide describes standard maintenance and relapse strategies for Multiple Myeloma. Treatment plans vary based on individual risk factors; consult your oncologist for personal advice.

Stay up to date

Get notified when new research about Multiple Myeloma is published.

No spam. Unsubscribe anytime.